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Figure S1: Confirmation of sialylated glycopeak structures by LC-MS  
The structures of the indicated glycopeaks (GP) were confirmed by LC-MS (more precisely, by HILIC-
UPLC-ESI-QTOF-MS/MS). (A) An exemplary fragmentation spectrum of GP26 (FA2G2Z2) is shown 
including an assignment of schematic drawings of the sugar structures for the major peaks (A). (B) 
Table summarizing the mass spectrometric analysis of GPs corresponding to sialylated glycan 
structures (GP18, 20, 21, and GP23-26). Calculated mass and m/z-ratios of singly ([M+H]+) and doubly 
charged ([M+2H]2+) glycan species, composition, proposed structure and respective comments are 
listed for each GP. Structure abbreviations: F, a core fucose α1–6 linked to the inner N-
acetylglucosamine (GlcNAc); Ax, number of antenna (GlcNAc); B, bisecting GlcNAc linked β1–4 to 
mannose; Gx, number of β1–4 linked galactose (G) on antenna; αGx, number of α1–3 linked galactose 
linked to β1–4 galactose; Sx, number of N-acetylneuraminic acids (S) linked to β1–4 galactose; Zx, 
number of N-glycolylneuraminic acids (Z) linked to β1–4 galactose; Ac, O-Acetylation. 
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Figure S2: Nomenclature, annotation and structure of different glycan peaks 
Depicted are the annotations and structures of each glycopeak obtained by HILIC-UPLC-FLR (A) and 
xCGE-LIF (B) analysis. For HILIC-UPLC-FLR annotation and structure is discriminated between 
human and mouse IgG glycoforms. Schematic drawings of the sugar structures for the respective peaks 
are depicted. The Figure legend at the bottom of the Figure depicts the symbols used for individual 
sugar residues. Structure abbreviations: F, a core fucose α1–6 linked to the inner N-acetylglucosamine 
(GlcNAc); Ax, number of antenna (GlcNAc); B, bisecting GlcNAc linked β1–4 to mannose; Gx, 
number of β1–4 linked galactose (G) on antenna; G1[3] and G1[6] indicates that the galactose is on the 
antenna of the α1–3 or α1–6 mannose; αGx, number of α1-3 linked galactose linked to β1–4 galactose; 
Sx, number of N-acetylneuraminic acids (S) linked to β1–4 galactose; Zx, number of N-
glycolylneuraminic acids (Z) linked to β1–4 galactose; Ac, O-Acetylation. 
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Figure S3: IVIg antibody half-life and kinetics of appearance of de novo sialylated IgG 
glycoforms as obtained by HILIC-UPLC-FLR  
(A) Depicted is the fold change of human IgG concentrations in the sera of IVIg or neuraminidase 
treated IVIg (NeuIVIg) injected ST6Gal1-/- mice at the indicated time points. (B, C) Shown are the 
relative changes (% of total IgG glycoforms in the preparation) in glycopeaks (GP) 18, 20, 25 and 26 
of IVIg (B) or neuraminidase treated IVIg (C) two, four, and six days after injection into µMT and 
ST6Gal1 deficient mice by HILIC-UPLC-FLR analysis. Bars represent mean ± SD. *p=0.05, 
**p=0.01. ***p=0.001, ****p=0.0001 by repeated measures two-way ANOVA. n=4-5. In each Figure, 
a schematic drawing of the sugar structure for the respective glycopeak is depicted. 
 
 
Figure S4: Representative murine and human IgG glycan profile detected with xCGE-LIF 
analysis 
Shown are representative chromatograms of murine (blue) and human (black) IgG glycan profiles 
obtained by xCGE-LIF analysis. Schematic drawing of the sugar structure for each individual 
glycopeak (P1 – P29) is depicted (human structures on top, mouse structures on the bottom). The 
Figure legend at the upper right of the Figure depicts the symbols used for individual sugar residues. 
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Figure S5: Kinetics of different IgG glycoforms as obtained by xCGE-LIF analysis. 
(A, B) Shown are the relative changes (% of total IgG glycoforms in the preparation) of the sialylated 
(Z), agalactosylated (G0), monogalactosylated (G1) and digalactosylated (G2) glycoforms of IVIg 
(A) or neuraminidase treated IVIg (B) two, four, and six days after injection into µMT and ST6Gal1 
deficient mice by xCGE-LIF analysis. Bars represent mean ± SD. *p=0.05, **p=0.01. ***p=0.001, 
by repeated measures two-way ANOVA. n=4-5. n.d.: not detectable. 
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Figure S6: Kinetics of appearance of de novo sialylated IgG glycoforms on murine IgG. 
(A) Shown is a representative overlay of xCGE-LIF IgG glycoanalysis of TA99 ten minutes as well 
as two, four and six days after injection into μMT mice (μMT TA99 10 min/d2/d4/d6). Clearly 
identifiable glycan peaks are annotated with their respective schematic drawing of the sugar 
structure. (B) Shown are the relative changes (% of total IgG glycoforms in the preparation) in 
glycopeaks (P) 2, 4 and 11 of TA99 ten minutes as well as two, four, and six days after injection into 
µMT mice by xCGE-LIF analysis for individual mice (n=4). In the bottom of each Figure a 
representative xCGE-LIF trace of glycopeaks P2, 4 and 11 is depicted (colors of individual traces 
correspond to Fig. S6A). P13 was not clearly identifiable and therefore was not determined (n.d.). In 
each Figure a schematic drawing of the sugar structure for the respective glycopeak is shown. 
Abbreviations: MTU’’: normalized migration time units. 
